Amgen's earnings call highlighted strong Q2 performance with revenue and earnings growth exceeding expectations, prompting an upward guidance revision for 2014.  The announcement of a restructuring plan, including workforce reductions and facility closures, is likely to negatively impact the stock price short-term due to the associated charges and investor questions about the strategy's long-term impact and reallocation of resources.
[-1]
